Safe Supply secures exclusive Canadian rights to GLP-1 spray technology
Safe Supply Streaming Co Ltd. (CSE: SPLY) announced it has entered into an exclusive licensing agreement with Healthy Sprays LLC for Canadian distribution rights to GLP-1 spray products. The five-year agreement begins in January 2026 and includes extension provisions.
Under the licensing agreement, Safe Supply will pay Healthy Sprays a $250,000 upfront license fee in tranches, plus royalties on Canadian gross sales. The company will purchase all product packaging and delivery technology directly from Healthy Sprays at a fixed cost. The agreement establishes minimum net sales requirements for each contract year.
Healthy Sprays' product line includes THIN (3.0 mg GLP-1 spray), THIN-R (7.2 mg GLP-1 spray), and THIN-ST (5.0 mg tirzepatide spray). The products use a proprietary sublingual spray delivery technology designed as a needle-free alternative to injectable GLP-1 therapies.
Safe Supply also announced a non-brokered private placement offering of up to C$500,000. The company will sell units at C$0.05 each, with each unit consisting of one common share and one-half warrant. The warrants are exercisable at C$0.075 per share for two years from closing.
The net proceeds from the offering will fund the licensing fee, expenses related to the licensing agreement, and general corporate purposes. The company may pay finders' fees of up to 7% cash and 7% broker's warrants to eligible finders.
The offering is subject to regulatory approvals, including approval from the Canadian Securities Exchange. All securities will be subject to a four-month statutory hold period from the date of issuance.
You May Also Be Interested In
- Ashland said to explore sale amid takeover interest - Bloomberg
- Rockstar Energy founder seeks CEO role at Celsius Holdings
- Dover Corp. (DOV) Raises Quarterly Dividend 1% to $0.525; 1% Yield
Create E-mail Alert Related Categories
Equity OfferingsRelated Entities
Maynard Um, Mark Zuckerberg, FDA, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share